Perceptive Advisors’s Zosano Pharma Corporation ZSAN Stock Holding History

Perceptive Advisors’s Portfolio ZSAN Stock Details ZSAN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-714	Closed	-$260K	–	161
2017 Q4	$260K	Hold	714	–	–	0.01%	128
2017 Q3	$412K	Hold	714	–	–	0.02%	130
2017 Q2	$705K	Hold	714	–	–	0.04%	104
2017 Q1	$950K	Buy	+714	New	+$862K	0.05%	97

Other funds holding ZSAN

Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return

IHM

Iguana Healthcare Management New York $152M AUM 48.74% 1-Year Est. Return

MIM

Monashee Investment Management Boston, Massachusetts $59.6M AUM 181.61% 1-Year Est. Return

CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Sabby Management Miami Beach, Florida $111M AUM 74.4% 1-Year Est. Return

HRCM

Hawk Ridge Capital Management Los Angeles, California $3.12B AUM 53.42% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return

Perceptive Advisors's ZSAN Position: Q1 2018 in Review

Perceptive Advisors sold out of Zosano Pharma Corporation (ZSAN) in Q1 2018, closing a stake of 714 shares — an estimated $260K sold.

Perceptive Advisors first reported a position in ZSAN in Q1 2017 and held it in 4 quarters. The position peaked at $950K in Q1 2017. 32 funds tracked by Wall St. Rank hold ZSAN as of Q1 2018.

Perceptive Advisors reported no remaining Zosano Pharma Corporation position as of Q1 2018 after selling out during the quarter.
Perceptive Advisors sold 714 Zosano Pharma Corporation shares in Q1 2018, an estimated $260K.
Perceptive Advisors first reported a position in Zosano Pharma Corporation in Q1 2017 and held it in 4 quarters.
Perceptive Advisors's Zosano Pharma Corporation position peaked at $950K in Q1 2017.
32 funds tracked by Wall St. Rank held Zosano Pharma Corporation as of Q1 2018.

Based on Perceptive Advisors's 13F filing for Q1 2018, filed 15 May 2018.